Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

GHRP-6

Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2

Quick Stats
Studies 702
Trials 0
Score 3
2005 pubmed 17 citations

Growth hormone-releasing peptide-6 increases insulin-like growth factor-I mRNA levels and activates Akt in RCA-6 cells as a model of neuropeptide Y neurones.

Frago. L M LM; Pañeda. C C; Argente. J J; Chowen. J A JA

Key Findings

  • Chronic GHRP‑6 administration raises IGF‑I mRNA and phosphorylated Akt levels in the rat hypothalamus.
  • GHRP‑6 increases IGF‑I and NPY mRNA in hypothalamic neuronal cells (RCA‑6) and activates Akt.
  • Blocking Akt does not stop GHRP‑6‑induced NPY or IGF‑I production, indicating NPY rise is Akt‑independent.

Practical Outcomes

  • For biohackers, the study suggests GHRP‑6 may influence central pathways that regulate growth factors and appetite, potentially affecting metabolic health. However, the work is in rats and cell lines, so no direct dosing or performance guidance can be drawn. It reinforces existing ideas that GHRP‑6 has brain effects but doesn’t provide new actionable protocols.

Summary

In rats, giving GHRP-6 over time raises IGF‑I gene activity and activates a key growth‑signaling protein (Akt) in brain areas that control hunger. The peptide also boosts IGF‑I and the appetite‑stimulating peptide NPY in hypothalamic cells, but the NPY increase doesn’t rely on Akt. This shows GHRP-6 can affect brain chemistry linked to growth and metabolism, though the exact pathways are still unclear.

Abstract

Chronic systemic administration of growth hormone (GH)-releasing peptide-6 (GHRP-6), an agonist for the ghrelin receptor, to normal adult rats increases insulin-like growth factor (IGF)-I mRNA and phosphorylated Akt (pAkt) levels in various brain regions, including the hypothalamus. Because neuropeptide Y (NPY) neurones of the arcuate nucleus express receptors for ghrelin, we investigated whether these neurones increase their IGF-I and p-Akt levels in response to this agonist. In control rats, immunoreactive pAkt was practically undetectable; however, GHRP-6 increased p-Akt immunoreactivity in the arcuate nucleus, with a subset of neurones also being immunoreactive for NPY. Immunoreactivity for IGF-I was detected in NPY neurones in both experimental groups. To determine if activation of this intracellular pathway is involved in modulation of NPY synthesis RCA-6 cells, an embryonic rat hypothalamic neuronal cell line that expresses NPY was used. We found that GHRP-6 stimulates NPY and IGF-I mRNA synthesis and activates Akt in this cell line. Furthermore, inhibition of Akt activation by LY294002 treatment did not inhibit GHRP-6 induction of NPY or IGF-I synthesis. These results suggest that some of the effects of GHRP-6 may involve stimulation of local IGF-I production and Akt activation in NPY neurones in the arcuate nucleus. However, GHRP-6 stimulation of NPY production does not involve this second messenger pathway.

Study Information

Provider

pubmed

Year

2005

Date

2005-11-01T00:00:00.000Z

DOI

10.1111/j.1365-2826.2005.01347.x

Citations

17

References

52